Doo-Yeoun Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Doo-Yeoun Cho has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Kwang-Min Kim
Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of Korea
10 shared publicationsBom-Taeck Kim
9 shared publications- Kyu-Nam Kim
Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon 16499, Republic of Korea
6 shared publications Nam-Seok Joo
Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Republic of Korea
5 shared publicationsDuck-Joo Lee
Department of Family Practice & Community Health, Ajou University School of Medicine, Suwon, Korea
4 shared publicationsJae-Gook Shin
Inje University College of Medicine, Inje University Busan Paik Hospital, Busan 614-735, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 27 June 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (7) , 564
Outcomes Assessment of Sustainable and Innovatively Simple Lifestyle Modification at the Workplace-Drinking Electrolyzed-Reduced Water (OASIS-ERW): A Randomized, Double-Blind, Placebo-Controlled Trial
Oxidative stress has been associated with many diseases as well as aging. Electrolyzed-reduced water (ERW) has been suggested to reduce oxidative stress and improve antioxidant potential. This study investigated the effects of drinking ERW on biomarkers of oxidative stress and health-related indices in healthy adults. We conducted a randomized, double-blind, placebo-controlled clinical trial on 65 participants, who were allocated into two groups. Of these, 61 received intervention (32 with ERW and 29 MW [mineral water]). All participants were instructed to drink 1.5 L/day of ERW or MW for eight weeks. Biomarkers of oxidative stress and health-related indices were assessed at baseline as well as after 4 weeks and 8 weeks of intervention. Of the primary outcome variables assessed, diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential showed a significant interaction between the groups and time, with d-ROMs levels significantly decreased at 8 weeks in ERW compared to those in MW. Among the secondary outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a significant association observed between the group and time. Thus, daily ERW consumption may be a potential consideration for a sustainable and innovatively simple lifestyle modification at the workplace to reduce oxidative stress, increase antioxidant potential, and decrease fat mass.
- 27 June 2020
- Published by MDPI AG in Antioxidants
- Vol. 9 (7) , 564
Open AccessOutcomes Assessment of Sustainable and Innovatively Simple Lifestyle Modification at the Workplace-Drinking Electrolyzed-Reduced Water (OASIS-ERW): A Randomized, Double-Blind, Placebo-Controlled Trial
Oxidative stress has been associated with many diseases as well as aging. Electrolyzed-reduced water (ERW) has been suggested to reduce oxidative stress and improve antioxidant potential. This study investigated the effects of drinking ERW on biomarkers of oxidative stress and health-related indices in healthy adults. We conducted a randomized, double-blind, placebo-controlled clinical trial on 65 participants, who were allocated into two groups. Of these, 61 received intervention (32 with ERW and 29 MW [mineral water]). All participants were instructed to drink 1.5 L/day of ERW or MW for eight weeks. Biomarkers of oxidative stress and health-related indices were assessed at baseline as well as after 4 weeks and 8 weeks of intervention. Of the primary outcome variables assessed, diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential showed a significant interaction between the groups and time, with d-ROMs levels significantly decreased at 8 weeks in ERW compared to those in MW. Among the secondary outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a significant association observed between the group and time. Thus, daily ERW consumption may be a potential consideration for a sustainable and innovatively simple lifestyle modification at the workplace to reduce oxidative stress, increase antioxidant potential, and decrease fat mass.
- Open Access
- 20 November 2019
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 17 (4) , 475-486
Biological Aspects of Aggression and Violence in Schizophrenia
WonKyung Cho, Won-Suk Shin, Iseul An, Minji Bang, Doo-Yeoun Cho, Sang-Hyuk Lee. Clin Psychopharmacol Neurosci 2019;17:475-86. https://doi.org/10.9758/cpn.2019.17.4.475
- 20 November 2019
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 17 (4) , 475-486
Open AccessBiological Aspects of Aggression and Violence in Schizophrenia
WonKyung Cho, Won-Suk Shin, Iseul An, Minji Bang, Doo-Yeoun Cho, Sang-Hyuk Lee. Clin Psychopharmacol Neurosci 2019;17:475-86. https://doi.org/10.9758/cpn.2019.17.4.475
- 1 August 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 57 (08) , 408-415
Pharmacokinetic study of two extended-release formulations of cilostazol in healthy Korean subjects: A randomized, open-label, multiple-dose, two-period crossover study
The aim of this study was to compare the pharmacokinetic characteristics and safety of two extended-release formulations of cilostazol after multiple oral doses in healthy Korean subjects. A randomized, open-label, multiple-dose, two-period, crossover study was conducted in 30 healthy male subjects. In each treatment period, subjects received oral doses of 200 mg cilostazol SR (Pletaal SR Cap.) or cilostazol CR (Cilostan CR Tab.) once daily for 5 consecutive days, with a washout period of 9 days. Plasma concentrations of cilostazol and its metabolites were determined using a validated liquid chromatography-tandem mass spectrometry method. 24 subjects completed the study. The maximum plasma concentrations (Cmax,ss, geometric mean (geometric coefficient of variation, CV%)) of cilostazol after cilostazol SR and cilostazol CR regimens were 1,532.7 (43.2%) ng/mL and 548.3 (58.9%) ng/mL, respectively, and the areas under the plasma concentration-time curves within dosing intervals (AUCτ, geometric mean (CV%)) were 17,060.7 (39.2%) h×ng/mL and 7,485.7 (55.0%) h×ng/mL, respectively. The geometric mean ratios (cilostazol SR/cilostazol CR) of the Cmax,ss and AUCτ values were 2.7954 (90% confidence interval: 2.3561 - 3.3166) and 2.2791 (90% confidence interval: 1.9770 - 2.6273), respectively. Both cilostazol SR and cilostazol CR were well tolerated in all subjects, and no serious adverse events occurred. The total incidence of headache, which is the most common adverse drug reaction, was significantly higher with cilostazol SR (63.0%) than cilostazol CR (25.9%). Cilostazol SR showed significantly higher Cmax and AUCτ of cilostazol than cilostazol CR after 5 days of multiple dosing of extended-release formulations of cilostazol.
- 1 August 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 57 (08) , 408-415
Pharmacokinetic study of two extended-release formulations of cilostazol in healthy Korean subjects: A randomized, open-label, multiple-dose, two-period crossover study
The aim of this study was to compare the pharmacokinetic characteristics and safety of two extended-release formulations of cilostazol after multiple oral doses in healthy Korean subjects. A randomized, open-label, multiple-dose, two-period, crossover study was conducted in 30 healthy male subjects. In each treatment period, subjects received oral doses of 200 mg cilostazol SR (Pletaal SR Cap.) or cilostazol CR (Cilostan CR Tab.) once daily for 5 consecutive days, with a washout period of 9 days. Plasma concentrations of cilostazol and its metabolites were determined using a validated liquid chromatography-tandem mass spectrometry method. 24 subjects completed the study. The maximum plasma concentrations (Cmax,ss, geometric mean (geometric coefficient of variation, CV%)) of cilostazol after cilostazol SR and cilostazol CR regimens were 1,532.7 (43.2%) ng/mL and 548.3 (58.9%) ng/mL, respectively, and the areas under the plasma concentration-time curves within dosing intervals (AUCτ, geometric mean (CV%)) were 17,060.7 (39.2%) h×ng/mL and 7,485.7 (55.0%) h×ng/mL, respectively. The geometric mean ratios (cilostazol SR/cilostazol CR) of the Cmax,ss and AUCτ values were 2.7954 (90% confidence interval: 2.3561 - 3.3166) and 2.2791 (90% confidence interval: 1.9770 - 2.6273), respectively. Both cilostazol SR and cilostazol CR were well tolerated in all subjects, and no serious adverse events occurred. The total incidence of headache, which is the most common adverse drug reaction, was significantly higher with cilostazol SR (63.0%) than cilostazol CR (25.9%). Cilostazol SR showed significantly higher Cmax and AUCτ of cilostazol than cilostazol CR after 5 days of multiple dosing of extended-release formulations of cilostazol.
- Open Access
- 1 March 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 1011-1022
A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
Background: KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson’s disease as a disease-modifying drug. Methods: This first-in-human, single and multiple ascending dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 in healthy volunteers. Additionally, the effect of age on safety and pharmacokinetics were assessed. The starting dose was determined considering the no observed adverse effect level based on preclinical studies, and the dose escalations in subsequent cohorts were decided based on safety, tolerability, and pharmacokinetic data from previous dose cohorts. Results: After a single dose, the KM-819 plasma exposure showed a less than dose-proportional increase across a dose range of 10–400 mg. After repeated dosing, KM-819 plasma exposure increased in an approximately dose-proportional manner across the evaluated dose range (30–400 mg once daily for 7 days). The mean elimination half-life was 1.8 to 4.8 h with the lower KM-819 doses (≤30 mg), which increased to around 9 h with the higher doses (100–400 mg). When administered to the elderly population, KM-819 plasma exposure increased to 102% after a 200 mg once-daily dosing for 7 days. No clear treatment-related effects on the estimated pharmacodynamic variables were observed. Single or multiple doses of KM-819 were generally well tolerated. Conclusion: The data from this study can be used to guide rational drug dosing and choose therapeutic regimens in subsequent clinical studies.
- 1 March 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 1011-1022
Open AccessA first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
Background: KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson’s disease as a disease-modifying drug. Methods: This first-in-human, single and multiple ascending dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 in healthy volunteers. Additionally, the effect of age on safety and pharmacokinetics were assessed. The starting dose was determined considering the no observed adverse effect level based on preclinical studies, and the dose escalations in subsequent cohorts were decided based on safety, tolerability, and pharmacokinetic data from previous dose cohorts. Results: After a single dose, the KM-819 plasma exposure showed a less than dose-proportional increase across a dose range of 10–400 mg. After repeated dosing, KM-819 plasma exposure increased in an approximately dose-proportional manner across the evaluated dose range (30–400 mg once daily for 7 days). The mean elimination half-life was 1.8 to 4.8 h with the lower KM-819 doses (≤30 mg), which increased to around 9 h with the higher doses (100–400 mg). When administered to the elderly population, KM-819 plasma exposure increased to 102% after a 200 mg once-daily dosing for 7 days. No clear treatment-related effects on the estimated pharmacodynamic variables were observed. Single or multiple doses of KM-819 were generally well tolerated. Conclusion: The data from this study can be used to guide rational drug dosing and choose therapeutic regimens in subsequent clinical studies.
- Open Access
- 9 May 2018
- Published by Wiley in Pain Research and Management
- Vol. 2018, 1-6
Reliability and Validity of the Korean Version of the Multidimensional Fatigue Inventory (MFI-20): A Multicenter, Cross-Sectional Study
Introduction. A nonspecific symptom, fatigue accompanies a variety of diseases, including cancer, and can have a grave impact on patients’ quality of life. As for multidimensional instruments, one of the most widely used is the Multidimensional Fatigue Inventory (MFI). This study aims to verify the reliability and validity of the MFI Korean (MFI-K) version. Materials and Method. This study was performed at four university hospitals in the Republic of Korea. Among outpatients visiting the Department of Family Medicine, those complaining of fatigue or visiting a chronic care clinic were enrolled in this study. A total of 595 participants were included, and the mean age was 42.2 years. Results. The Cronbach’s alpha coefficient of the MFI-K was 0.88. The MFI-K had good convergent validity. Most subscales of the MFI-K were significantly correlated with the Visual Analogue Scale (VAS) and Fatigue Severity Scale (FSS). In particular, general and physical fatigue had the greatest correlation with the VAS and FSS. Although the English version of MFI had five subscales, the factor analysis led to four subscales in the Korean version. Conclusion. This study demonstrated the clinical usefulness of MFI-K instrument, particularly in assessing the degree of fatigue and performing a multidimensional assessment of fatigue.
- 9 May 2018
- Published by Wiley in Pain Research and Management
- Vol. 2018, 1-6
Open AccessReliability and Validity of the Korean Version of the Multidimensional Fatigue Inventory (MFI-20): A Multicenter, Cross-Sectional Study
Introduction. A nonspecific symptom, fatigue accompanies a variety of diseases, including cancer, and can have a grave impact on patients’ quality of life. As for multidimensional instruments, one of the most widely used is the Multidimensional Fatigue Inventory (MFI). This study aims to verify the reliability and validity of the MFI Korean (MFI-K) version. Materials and Method. This study was performed at four university hospitals in the Republic of Korea. Among outpatients visiting the Department of Family Medicine, those complaining of fatigue or visiting a chronic care clinic were enrolled in this study. A total of 595 participants were included, and the mean age was 42.2 years. Results. The Cronbach’s alpha coefficient of the MFI-K was 0.88. The MFI-K had good convergent validity. Most subscales of the MFI-K were significantly correlated with the Visual Analogue Scale (VAS) and Fatigue Severity Scale (FSS). In particular, general and physical fatigue had the greatest correlation with the VAS and FSS. Although the English version of MFI had five subscales, the factor analysis led to four subscales in the Korean version. Conclusion. This study demonstrated the clinical usefulness of MFI-K instrument, particularly in assessing the degree of fatigue and performing a multidimensional assessment of fatigue.
- 15 January 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 29 (1) , 52-60
The relationship of alanine aminotransferase to metabolic syndrome in a Korean population
Background/Aims: Although associations between serum alanine aminotransferase and metabolic syndrome are well-recognized in Western countries, only a limited number of prospective studies have been performed in Asian populations. The aim of the study was to cross-sectionally and longitudinally examine whether serum alanine aminotransferase levels are associated with metabolic syndrome and its associated components in a Korean population. Materials and Methods: A total of 31,832 subjects who received health screenings were included in cross-sectional analyses; a subgroup of 4.070 subjects without metabolic syndrome at baseline was included in the longitudinal analyses. The metabolic syndrome definition was based on the National Cholesterol Education Program Third Adult Treatment Panel criteria with modification on waist circumference cut-off to be more appropriate for an Asian population. Results: In the cross-sectional analyses, serum alanine aminotransferase is positively associated with metabolic syndrome and its components. In the longitudinal analyses, the prevalence of metabolic syndrome increased across serum alanine aminotransferase quartiles in a dose-dependent manner after extensive adjustments (hazard ratios were 1.000, 1.609, 2.601, and 3.015 for quartiles, 1 through quartile 4; P for trend Conclusion: Our study confirmed a positive association between components of metabolic syndrome and elevated serum alanine aminotransferase in a Korean population. Cite this article as: Lee SH, Cho DY, Joo NS, Kim KM, Kim KN. The relationship of alanine aminotransferase to metabolic syndrome in a Korean population. Turk J Gastroenterol 2018; 29: 50-7.
- 15 January 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 29 (1) , 52-60
The relationship of alanine aminotransferase to metabolic syndrome in a Korean population
Background/Aims: Although associations between serum alanine aminotransferase and metabolic syndrome are well-recognized in Western countries, only a limited number of prospective studies have been performed in Asian populations. The aim of the study was to cross-sectionally and longitudinally examine whether serum alanine aminotransferase levels are associated with metabolic syndrome and its associated components in a Korean population. Materials and Methods: A total of 31,832 subjects who received health screenings were included in cross-sectional analyses; a subgroup of 4.070 subjects without metabolic syndrome at baseline was included in the longitudinal analyses. The metabolic syndrome definition was based on the National Cholesterol Education Program Third Adult Treatment Panel criteria with modification on waist circumference cut-off to be more appropriate for an Asian population. Results: In the cross-sectional analyses, serum alanine aminotransferase is positively associated with metabolic syndrome and its components. In the longitudinal analyses, the prevalence of metabolic syndrome increased across serum alanine aminotransferase quartiles in a dose-dependent manner after extensive adjustments (hazard ratios were 1.000, 1.609, 2.601, and 3.015 for quartiles, 1 through quartile 4; P for trend Conclusion: Our study confirmed a positive association between components of metabolic syndrome and elevated serum alanine aminotransferase in a Korean population. Cite this article as: Lee SH, Cho DY, Joo NS, Kim KM, Kim KN. The relationship of alanine aminotransferase to metabolic syndrome in a Korean population. Turk J Gastroenterol 2018; 29: 50-7.
- Open Access
- 30 October 2017
- Published by Wiley in International Journal of Endocrinology
- Vol. 2017, 1-7
Low Levels of Sex Hormone-Binding Globulin Constitute an Independent Risk Factor for Arterial Stiffness in Korean Women
The association between sex hormone-binding globulin (SHBG) and arterial stiffness in women is not conclusive. In addition, obesity might also be involved in the relationship between SHBG and atherosclerosis. The aim of this study was to determine the relationship between SHBG and arterial stiffness in association with central obesity in women. This cross-sectional study included 381 women who participated in the health checkup programs in one hospital. The brachial-ankle pulse wave velocity (baPWV) was measured as a marker for arterial stiffness. A negative correlation was observed between SHBG levels and baPWV (rho = −0.281). The relationship was significant even after adjusting for potential confounders (beta = −0.087 in fully adjusted model). After considering the interaction between central obesity and SHBG levels, the significant association was evident only in obese women (for interaction = 0.025). Adjustment for a 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores, instead of each cardiovascular risk factor individually, did not affect the significance of the relationship between SHBG levels and baPWV. Serum levels of SHBG were negatively associated with arterial stiffness independent of cardiovascular risk factors or 10-year ASCVD risk scores in Korean women. The relationship may be potentiated by central obesity.- 30 October 2017
- Published by Wiley in International Journal of Endocrinology
- Vol. 2017, 1-7
Open AccessLow Levels of Sex Hormone-Binding Globulin Constitute an Independent Risk Factor for Arterial Stiffness in Korean Women
The association between sex hormone-binding globulin (SHBG) and arterial stiffness in women is not conclusive. In addition, obesity might also be involved in the relationship between SHBG and atherosclerosis. The aim of this study was to determine the relationship between SHBG and arterial stiffness in association with central obesity in women. This cross-sectional study included 381 women who participated in the health checkup programs in one hospital. The brachial-ankle pulse wave velocity (baPWV) was measured as a marker for arterial stiffness. A negative correlation was observed between SHBG levels and baPWV (rho = −0.281). The relationship was significant even after adjusting for potential confounders (beta = −0.087 in fully adjusted model). After considering the interaction between central obesity and SHBG levels, the significant association was evident only in obese women (for interaction = 0.025). Adjustment for a 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores, instead of each cardiovascular risk factor individually, did not affect the significance of the relationship between SHBG levels and baPWV. Serum levels of SHBG were negatively associated with arterial stiffness independent of cardiovascular risk factors or 10-year ASCVD risk scores in Korean women. The relationship may be potentiated by central obesity. - 23 January 2017
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 7 (1) , 53-58
Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed‐Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects
CDFR0209, a combination of an immediate‐release formulation of omeprazole 40 mg and sodium bicarbonate 1100 mg, has been developed to treat acid‐related disorders. We compared the acid inhibitory effects of CDFR0209 and delayed‐release omeprazole (omeprazole‐DR, Losec 40 mg) after repeated dosing in Helicobacter pylori–negative healthy adult male subjects. In this 2‐period crossover study, 30 subjects were randomized to CDFR0209 or omeprazole‐DR daily for 7 days. An ambulatory continuous 24‐hour intragastric pH recording was performed at baseline and on days 1 and 7 of each administration period. Integrated gastric acidity was calculated from time‐weighted average hydrogen ion concentrations at each hour of the 24‐hour record. An analysis of variance model was used to test the pharmacodynamic equivalence of CDFR0209 and omeprazole‐DR, using the natural logarithmic transformation of the percent decrease from baseline in integrated gastric acidity for the 24‐hour interval after the seventh dose of each omeprazole formulation. The geometric least‐squares mean ratios (CDFR0209/omeprazole‐DR) of the percent decrease from baseline in integrated gastric acidity was 0.98 (90%CI, 0.93–1.07). Both CDFR0209 and omeprazole‐DR are equally effective in decreasing integrated gastric acidity at steady state.
- 23 January 2017
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 7 (1) , 53-58
Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed‐Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects
CDFR0209, a combination of an immediate‐release formulation of omeprazole 40 mg and sodium bicarbonate 1100 mg, has been developed to treat acid‐related disorders. We compared the acid inhibitory effects of CDFR0209 and delayed‐release omeprazole (omeprazole‐DR, Losec 40 mg) after repeated dosing in Helicobacter pylori–negative healthy adult male subjects. In this 2‐period crossover study, 30 subjects were randomized to CDFR0209 or omeprazole‐DR daily for 7 days. An ambulatory continuous 24‐hour intragastric pH recording was performed at baseline and on days 1 and 7 of each administration period. Integrated gastric acidity was calculated from time‐weighted average hydrogen ion concentrations at each hour of the 24‐hour record. An analysis of variance model was used to test the pharmacodynamic equivalence of CDFR0209 and omeprazole‐DR, using the natural logarithmic transformation of the percent decrease from baseline in integrated gastric acidity for the 24‐hour interval after the seventh dose of each omeprazole formulation. The geometric least‐squares mean ratios (CDFR0209/omeprazole‐DR) of the percent decrease from baseline in integrated gastric acidity was 0.98 (90%CI, 0.93–1.07). Both CDFR0209 and omeprazole‐DR are equally effective in decreasing integrated gastric acidity at steady state.
- Open Access
- 1 November 2016
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 36 (6) , 595-598
Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment
Min-Young Kim, M.D., Kyu-Nam Kim, M.D., Hye-Min Cho, M.D., Duck-Joo Lee, M.D., and Doo-Yeoun Cho, M.D.. Ann Lab Med 2016;36:595-8. https://doi.org/10.3343/alm.2016.36.6.595
- 1 November 2016
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 36 (6) , 595-598
Open AccessReference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment
Min-Young Kim, M.D., Kyu-Nam Kim, M.D., Hye-Min Cho, M.D., Duck-Joo Lee, M.D., and Doo-Yeoun Cho, M.D.. Ann Lab Med 2016;36:595-8. https://doi.org/10.3343/alm.2016.36.6.595
- 6 October 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (11) , 1372-1377
The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects
Udenafil, a cyclic guanosine monophosphate–specific phosphodiesterase type 5 inhibitor, has been developed to treat erectile dysfunction. We evaluated the effect of age on the pharmacokinetics and tolerability of udenafil. A single-center, open-label, parallel-group phase 1 study was conducted in healthy adult subjects who took a single oral dose of udenafil (100 mg). The pharmacokinetics and tolerability of udenafil were compared between 12 healthy young men (21–27 years) and 12 healthy elderly men (65–78 years). Serial blood and urine samples were collected for up to 60 and 48 hours after dosing. The plasma concentrations of udenafil and its major metabolite, DA-8164, were analyzed using a validated liquid chromatography-tandem mass spectrometry method. The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9–97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1–108.4). The mean t1/2 was prolonged by approximately 5 hours in the elderly (P < .05). The clearance and metabolic AUC ratio did not differ between the elderly and young. In terms of tolerability, all adverse events were mild, and all subjects recovered without additional therapy. The systemic exposure of elderly subjects to udenafil appears to be comparable to or slightly less than that of young healthy subjects. Based on our pharmacokinetic comparisons, udenafil dose adjustment is unlikely to be required in the elderly population.
- 6 October 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (11) , 1372-1377
The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects
Udenafil, a cyclic guanosine monophosphate–specific phosphodiesterase type 5 inhibitor, has been developed to treat erectile dysfunction. We evaluated the effect of age on the pharmacokinetics and tolerability of udenafil. A single-center, open-label, parallel-group phase 1 study was conducted in healthy adult subjects who took a single oral dose of udenafil (100 mg). The pharmacokinetics and tolerability of udenafil were compared between 12 healthy young men (21–27 years) and 12 healthy elderly men (65–78 years). Serial blood and urine samples were collected for up to 60 and 48 hours after dosing. The plasma concentrations of udenafil and its major metabolite, DA-8164, were analyzed using a validated liquid chromatography-tandem mass spectrometry method. The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9–97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1–108.4). The mean t1/2 was prolonged by approximately 5 hours in the elderly (P < .05). The clearance and metabolic AUC ratio did not differ between the elderly and young. In terms of tolerability, all adverse events were mild, and all subjects recovered without additional therapy. The systemic exposure of elderly subjects to udenafil appears to be comparable to or slightly less than that of young healthy subjects. Based on our pharmacokinetic comparisons, udenafil dose adjustment is unlikely to be required in the elderly population.